From: Ovarian fibrosarcoma: A single-institution experience and a review of the literature
NO. | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
---|---|---|---|---|---|
Age, (year) | 57 | 41 | 76 | 76 | 51 |
Menopausal status | Yes | No | Yes | Yes | Yes |
Gravidity/ Parity | 1/1 | 2/1 | 4/4 | 1/1 | 1/1 |
Clinical presentations | Mass | Mass | Mass, pain, fever | Mass, pain | Mass, pain, fever |
Ultrasound | Thickly capsulated, 9.6*8.2*5.2 cm, irregular, left; septa inside; small amount of blood flow signal; liquid depth 4.6 cm. | Heterogeneous, left, clear boundary, 6.1*5.5*4.6 cm. | Irregular, cystic, 10*8.6 cm, unclear boundary, uneven in thickness. | Heterogeneous, irregular, hypoechoic, unclear boundary, 11.4*13.5*8.6 cm; punctiform blood flow signals; liquid depth 1.6 cm. | Solid, clear boundaries, 7.3*5.9*6.5 cm, abundant arteriovenous blood flow signals. |
Size of mass, cm | 8*10 | 7*6 | 10 | 20 | 10*15 |
Side of mass | Right | Left | Left | Left | Left |
CA 125, U/ml (normal range ≤ 35 U/ml) | 9.9 | 40.4 | 15.5 | 593.3 | 88.8 |
Surgery | TAH + BSO | Ovarian cystectomy + sampling of right ovary. | Secondary cytoreductive surgery | Left adnexectomy | TAH + BSO; Partial removal of pelvic mass |
FIGO Stage | IC | IA | - | IIIC | II |
Intraoperative pathology | NA | Left ovarian follicular fibroma | NA | NA | Sexostromal tumor, not excluding malignant tumor. |
Final pathology | Well-differentiated fibrosarcoma | Fibrosarcoma | Fibrosarcoma | Fibrosarcoma | Fibrosarcoma |
Mitotic counts/ HPF | - | > 10 | - | > 10 | > 40 |
Ki-67 | - | 5% | 10% | 40% | 70% |
Immunohistochemistry | Vimentin (+), SMA (+), PR (±), ER (-), CD10 (-), Caldeson (-), Melan (-), α-inhibin (-). | AE1/AE3 (-), Calretinin (-), Ki-67 (index 5%), p53 (-), α-inhibin (-). | Melan-A (+), Vimentin (+), AE1/AE3 (+/-), CD99 (-), Calretinin (-), α-inhibin (-), Ki-67 (index10%). | CA125 (-), CD10 (partial+), Desmin (-), Ki-67 (index40%), SMA (+), S-100 (-), Vimentin (+), p53 (-), α-inhibin(-). | CD31(+), Ki-67(+ 70%), SMA(+), AE1/AE3(-), CD34(-), CD117(-), ER(-), PR(-), Desmin(-). |
Adjuvant therapy | PVB*2 | No | No | No | PEI; TC |
Relapse | No | No | No | Yes | Yes |
OS, y | > 15 | > 7 | > 6 | < 1 | < 1 |